The company's financial position is increasingly vulnerable, highlighted by a sharp decline in total assets to $13.6M and an accumulated deficit reaching $404.5M by 2026Q2.
| Total Current Assets | 2.68M | 2.24M |
| Cash & Short-Term Investments | 949.09K | 1.67M |
| Cash Only | 949.09K | 1.67M |
| Short-Term Investments | 0 | 0 |
| Accounts Receivable | 303.26K | 237.4K |
| Days Sales Outstanding | 56.08 | 40.55 |
| Inventory | 115.39K | 84.1K |
| Days Inventory Outstanding | 48.45 | 23.65 |
| Other Current Assets | 1.31M | 249.12K |
| Total Non-Current Assets | 10.96M | 2.2M |
| Property, Plant & Equipment | 173.73K | 435.97K |
| Fixed Asset Turnover | 4.93x | 4.90x |
| Goodwill | 0 | 0 |
| Intangible Assets | 1.34M | 0 |
| Long-Term Investments | 9.86M | 750K |
| Other Non-Current Assets | 333.18K | 1.01M |
| Total Assets | 13.63M | 4.44M |
| Asset Turnover | 0.17x | 0.48x |
| Asset Growth % | -71.59% | - |
| Total Current Liabilities | 1.47M | 2.46M |
| Accounts Payable | 839.56K | 844.78K |
| Days Payables Outstanding | 273.89 | 237.55 |
| Short-Term Debt | 0 | 0 |
| Deferred Revenue (Current) | 28.34K | 12.29K |
| Other Current Liabilities | 322.35K | 285.32K |
| Current Ratio | 1.82x | 0.91x |
| Quick Ratio | 1.74x | 0.87x |
| Cash Conversion Cycle | -169.36 | -173.35 |
| Total Non-Current Liabilities | 31.47K | 31.84K |
| Long-Term Debt | 0 | 0 |
| Capital Lease Obligations | 0 | 0 |
| Deferred Tax Liabilities | 684.12K | 0 |
| Other Non-Current Liabilities | 31.47K | 31.84K |
| Total Liabilities | 1.5M | 2.5M |
| Total Debt | 0 | 193.25K |
| Net Debt | -949.09K | -1.47M |
| Debt / Equity | 0.00x | 0.10x |
| Debt / EBITDA | -0.00x | - |
| Net Debt / EBITDA | 0.04x | - |
| Interest Coverage | - | - |
| Total Equity | 12.13M | 1.94M |
| Equity Growth % | -55.49% | - |
| Book Value per Share | 1.25 | 3.75 |
| Total Shareholders' Equity | 12.51M | 2.3M |
| Common Stock | 5.67K | 1.66K |
| Retained Earnings | -404.45M | -379.16M |
| Treasury Stock | 0 | 0 |
| Accumulated OCI | 0 | 0 |
| Minority Interest | -375.61K | -363.05K |
Imminent liquidity and dilution
As reported in recent financial statements, BNBX's total assets have plummeted from $16.7M in 2024Q3 to $13.6M by 2026Q2, reflecting a consistent contraction that underscores the company's inability to stabilize its capital base while operating under a persistent, high-burn business model.
The downward trend in total assets suggests that the company is consuming its capital reserves faster than it can generate value through its diagnostic services. This trajectory indicates that the firm's current operational scale is not merely stagnant but actively shrinking, which may limit its future capacity to invest in necessary mRNA research and development.
Based on the latest quarterly data, BNBX's cash reserves have dwindled to $949.1K as of 2026Q2, a sharp decline from the $10.4M reported in 2024Q3, which signals an acute liquidity crisis that likely necessitates immediate and potentially dilutive external financing to maintain ongoing laboratory operations.
The rapid depletion of cash relative to the company's high operating overhead suggests that the current liquidity buffer is insufficient to support long-term commercialization efforts. Investors should monitor the current ratio, which, while appearing stable at 1.82, masks the reality that the underlying cash position is insufficient to cover even a single quarter of historical operating expenses.
According to the company's balance sheet, retained earnings have reached a staggering negative $404.5M as of 2026Q2, illustrating a profound and persistent history of value destruction that significantly undermines the quality of the firm's equity base for potential future investors.
The massive deficit in retained earnings highlights that the company has failed to achieve a return on invested capital, effectively eroding shareholder value over time. This persistent negative balance suggests that the equity structure is heavily reliant on continuous capital raises rather than organic growth, which may lead to significant dilution for existing shareholders.
As indicated by the provided financial records, BNBX's net PPE has declined to $173.7K in 2026Q2 from a peak of $1.4M in 2024Q3, suggesting a significant reduction in the physical infrastructure required to support its specialized mRNA diagnostic testing services.
The reduction in PPE suggests that the company may be scaling back its laboratory footprint or failing to maintain the equipment necessary for its diagnostic assays. This trend warrants further investigation, as it may indicate a strategic pivot or, more concerningly, a forced divestment of assets to preserve remaining cash for administrative survival.
Quick answers to the most common questions about buying BNBX stock.
As of 2025, BNB Plus Corp. (BNBX) had total assets of $4.4M including $2.2M in current assets.
BNB Plus Corp. (BNBX) carries total debt of $0.2M, offset by $1.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
BNB Plus Corp. (BNBX) has total shareholders' equity (book value) of $2.3M ($3.75 book value per share). Book value represents the net worth of the company belonging to common stock holders.
BNB Plus Corp. (BNBX) reported a current ratio of 0.91x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.